vida: extract claims from 2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes

- Source: inbox/queue/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/ai-alignment/voluntary-safety-constraints-without-external-enforcement-are-statements-of-intent-not-binding-governance.md

@@ -42,3 +42,10 @@ The White House AI EO represents a shift from voluntary commitments (CAISI volun
 **Source:** Breaking Defense, March 26, 2026 - Pentagon maintains ban despite injunction
 
 The administration's apparent defiance of a federal court preliminary injunction demonstrates that even judicial enforcement mechanisms may be circumvented through jurisdictional challenges and institutional inertia. Federal contracting officers may continue treating the Anthropic ban as operative despite the court order, preserving the de facto ban through bureaucratic compliance resistance rather than formal legal authority.
+
+
+## Supporting Evidence
+
+**Source:** METR Frontier AI Safety Regulations Reference, January 2026
+
+California SB 53 makes external evaluation voluntary (not mandatory) and accepts ISO/IEC 42001 as compliance evidence. METR's reference document identifies this as a 'self-reporting architecture' and notes the limitation was 'identified in prior Sessions as inadequate.' The voluntary third-party evaluation structure confirms that even statutory requirements can preserve voluntary compliance theater.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -25,3 +25,10 @@ The COMP005 trial achieved its primary endpoint with a statistically significant
 **Source:** Journal of Psychoactive Drugs PMC12304229, Oregon facilitator workforce survey 2023-2025
 
 Oregon's real-world implementation shows facilitators specializing in trauma (83%), mental health disorders (69%), and consciousness exploration (68%), with mean planned session cost of $1,388 — below current market of $1,500-3,000 but still unaffordable for most potential TRD patients without insurance coverage. The 7.5% capacity utilization (4,500 actual vs 60,000 theoretical clients/year) demonstrates that clinical efficacy alone is insufficient for population-level access.
+
+
+## Extending Evidence
+
+**Source:** Bendable Therapy Oregon Measure 109 study, March 2024-April 2025
+
+Oregon real-world naturalistic study shows large effect sizes at 30-day follow-up (PHQ-8: -4.63 points, d=0.90; GAD-7: -4.85 points, d=1.04; WHO-5: +10.67 points, d=2.14) with average dose 27.8mg TPE. However, follow-up limited to 30 days, preventing durability comparison with Compass Phase 3's 26-week endpoint. Study population differs from treatment-resistant depression trials: only 51.1% had depression diagnosis, 64.8% had prior psilocybin experience, and clients were self-selected paying customers rather than trial participants.

domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md

@@ -24,3 +24,10 @@ The COMP005 trial embedded psychological support as a mandatory protocol compone
 **Source:** Journal of Psychoactive Drugs PMC12304229, Oregon facilitator training and practice parameters
 
 Oregon facilitator training requires 120-200 hours coursework plus 40-hour practicum, with facilitators planning mean 18.6 hours/week service delivery for ~10 clients/month. This infrastructure investment confirms psychological support is not optional but structurally embedded in the legal psilocybin service model.
+
+
+## Supporting Evidence
+
+**Source:** Bendable Therapy Oregon study, 88 completers, 30-day follow-up
+
+80% of Oregon Measure 109 clients attended integration sessions following their psilocybin experience. The study site enhanced Oregon's minimum regulatory requirements with multiple preparation sessions and structured integration support. This high integration attendance rate among clients who achieved large effect sizes (d=0.90 for depression, d=1.04 for anxiety, d=2.14 for wellbeing) supports the mechanism that psychological support is integral to therapeutic outcomes.

entities/ai-alignment/california-sb-53.md

@@ -0,0 +1,33 @@
+# California SB 53
+
+**Type:** State AI safety legislation  
+**Status:** Effective January 1, 2026  
+**Jurisdiction:** California, United States
+
+## Overview
+
+California SB 53 is state-level frontier AI safety legislation that applies to developers of frontier AI models. The law establishes requirements for incident reporting, safety and security model evaluations, internal governance practices, and whistleblower protections.
+
+## Key Provisions
+
+**Scope:** Applies to developers of frontier AI models operating in California.
+
+**Requirements:**
+- Incident reporting obligations
+- Safety and security model evaluations
+- Internal governance practices
+- Whistleblower protections
+
+**External Evaluation:** Voluntary (not mandatory) under SB 53. The law accepts ISO/IEC 42001 (management system standard) as compliance evidence.
+
+## Limitations
+
+METR's regulatory reference identifies two key limitations:
+1. Voluntary third-party evaluation structure (identified as inadequate)
+2. ISO/IEC 42001 acceptance creates self-reporting architecture
+
+Both limitations were noted as previously identified in prior analysis as inadequate for meaningful safety governance.
+
+## Timeline
+
+- **2026-01-01** — SB 53 becomes effective, establishing California as first US state with frontier AI safety requirements

entities/ai-alignment/new-york-raise-act.md

@@ -0,0 +1,26 @@
+# New York RAISE Act
+
+**Type:** State AI safety legislation  
+**Status:** Legislative status unclear as of January 2026  
+**Jurisdiction:** New York, United States
+
+## Overview
+
+The New York RAISE Act is proposed state-level AI safety legislation with similar scope to California SB 53. The act has had contested legislative history.
+
+## Key Provisions
+
+**Scope:** Similar to California SB 53, targeting frontier AI model developers.
+
+**Requirements:**
+- Incident reporting
+- Model evaluation requirements
+- (Additional provisions not detailed in available reference)
+
+## Status
+
+As of January 2026, METR's regulatory reference notes the act's existence and contested legislative history but does not clarify current passage status or implementation timeline.
+
+## Timeline
+
+- **2025-2026** — Contested legislative process, status unclear as of January 2026

entities/health/bendable-therapy.md

@@ -0,0 +1,37 @@
+# Bendable Therapy
+
+**Type:** Psilocybin service center  
+**Location:** Portland, Oregon  
+**Status:** Operating under Oregon Measure 109  
+**Domain:** Psychedelic-assisted therapy
+
+## Overview
+
+Bendable Therapy is a psilocybin service center operating under Oregon's Measure 109 state-regulated psilocybin program. The center is notable for exceeding Oregon's minimum regulatory requirements by providing enhanced screening, multiple preparation sessions, and structured integration support.
+
+## Research
+
+Bendable Therapy conducted the first published outcomes study from Oregon's Measure 109 program, a prospective naturalistic study from March 2024 to April 2025. The study enrolled 91 clients with 88 completing all components, demonstrating large effect sizes for depression (d=0.90), anxiety (d=1.04), and wellbeing (d=2.14) at 30-day follow-up.
+
+## Service Model
+
+- Average dose: 27.8 mg Total Psilocybin Equivalents
+- Session format: 56.8% individual, 43.2% group
+- Integration: 80% client attendance rate
+- Enhanced protocol beyond Oregon minimum requirements
+
+## Client Demographics
+
+The center's client base reflects significant demographic disparities:
+- 87.5% white (vs. Oregon general population)
+- 84.1% completed higher education
+- 77.3% earning above $50K annually
+- 46.6% traveling from out of state
+- 64.8% with prior psilocybin experience
+- Median age 43 years
+
+## Timeline
+
+- **2024-03** — Began prospective naturalistic outcomes study
+- **2025-04** — Completed data collection for first Oregon Measure 109 outcomes study
+- **2026-02-18** — Published medRxiv preprint showing large effect sizes but significant demographic disparities in access

entities/health/oregon-measure-109.md

@@ -0,0 +1,49 @@
+# Oregon Measure 109
+
+**Type:** State psilocybin regulation  
+**Jurisdiction:** Oregon, USA  
+**Status:** Active (approved 2020, implemented 2023)  
+**Domain:** Psychedelic policy
+
+## Overview
+
+Measure 109 is Oregon's voter-approved ballot initiative establishing a state-regulated psilocybin services program. Passed in November 2020, it created the first legal framework in the United States for supervised psilocybin administration for therapeutic purposes outside of clinical trials.
+
+## Regulatory Framework
+
+- State licensing of psilocybin service centers
+- Facilitator training and certification requirements
+- Minimum protocol requirements for preparation, administration, and integration
+- No medical diagnosis required for access
+- Services available to adults 21+
+
+## Implementation
+
+The program became operational in 2023, with licensed service centers beginning to offer psilocybin sessions. Individual centers may exceed minimum regulatory requirements with enhanced screening, preparation, and integration protocols.
+
+## Access and Equity Issues
+
+First published outcomes data (Bendable Therapy, 2026) revealed significant demographic disparities:
+- 87.5% of clients are white
+- 84.1% have completed higher education
+- 77.3% earn above $50K annually
+- 46.6% travel from out of state
+- Program functions partly as "psilocybin tourism" destination
+
+These patterns indicate the program is not reaching underserved populations despite being designed for therapeutic mental health access.
+
+## Clinical Outcomes
+
+First naturalistic study (n=88, 30-day follow-up) showed large effect sizes:
+- Depression: -4.63 points PHQ-8, d=0.90
+- Anxiety: -4.85 points GAD-7, d=1.04
+- Wellbeing: +10.67 points WHO-5, d=2.14
+- Clinically significant HPPD at 30 days: 0%
+- Lingering negative effects: 3.4%
+
+## Timeline
+
+- **2020-11** — Measure 109 approved by Oregon voters
+- **2023** — Program implementation begins, licensed service centers open
+- **2024-03** — First prospective outcomes study begins (Bendable Therapy)
+- **2026-02-18** — First published outcomes study released as medRxiv preprint, revealing both strong clinical effects and significant demographic access disparities

inbox/archive/ai-alignment/2026-01-29-metr-frontier-ai-safety-regulations-reference.md

@@ -7,10 +7,13 @@ date: 2026-01-29
 domain: ai-alignment
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: theseus
+processed_date: 2026-05-11
 priority: medium
 tags: [metr, frontier-ai, safety-regulations, eu-ai-act, gpai, california-sb53, new-york-raise, regulatory-reference]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-02-18-medrxiv-oregon-psilocybin-services-mental-health-outcomes.md

@@ -7,10 +7,13 @@ date: 2026-02-18
 domain: health
 secondary_domains: []
 format: preprint
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: high
 tags: [psilocybin, Oregon, mental-health, access, demographic-data, outcomes, naturalistic-study]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content